IPP Bureau
Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies
By IPP Bureau - April 04, 2026
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma
By IPP Bureau - April 04, 2026
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Jan Vishwas Bill 2026 decriminalises minor health sector offences, eases compliance burden
By IPP Bureau - April 04, 2026
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
BASF Pharma Solutions announces up to 20% price hike on excipients and APIs
By IPP Bureau - April 04, 2026
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
Cipla strengthens US respiratory portfolio with final FDA nod for generic Nintedanib
By IPP Bureau - April 04, 2026
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Abbott launches nationwide Vitamin C awareness campaign
By IPP Bureau - April 04, 2026
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Kauvery Hospital sets new benchmark in high-risk cardiac care
By IPP Bureau - April 04, 2026
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
Apollo Hospitals hosts specialist dialogue on vertigo diagnosis challenges
By IPP Bureau - April 04, 2026
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
By IPP Bureau - April 03, 2026
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment
By IPP Bureau - April 03, 2026
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
By IPP Bureau - April 03, 2026
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra
By IPP Bureau - April 03, 2026
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
By IPP Bureau - April 03, 2026
Its a major breakthrough for women’s ovarian cancer care in Europe
Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness
By IPP Bureau - April 03, 2026
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells
By IPP Bureau - April 03, 2026
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
